$WAT News

Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026

Waters (WAT) Stock Looks 26% Overvalued On Cash Flow Estimates

Waters Launches AI Link to Advance AI-Enabled LC-MS Workflows

Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option

Earnings Preview: What to Expect From Waters Corporation’s Report

Here’s How Much You Would Have Made Owning Waters Stock In The Last 20 Years

Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release

Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release

TD Cowen Maintains Buy on Waters, Raises Price Target to $515

Barclays Maintains Overweight on Waters, Raises Price Target to $500

CellCarta, Waters Corporation collaborate on companion diagnostics

CellCarta Establishes Strategic Partnership with Waters to Advance Companion Diagnostics Development

Waters Corporation Schedules Third Quarter 2026 Earnings Conference Call

Guggenheim Maintains Buy on Waters, Raises Price Target to $490

If You Invested $1000 In Waters Stock 20 Years Ago, You Would Have This Much Today

The Bull Case For Waters (WAT) Could Change Following New At-Home HPV And Cell Analysis Push

Waters Tops Growth Outlook as AI Demand, BD Integration Fuel Momentum

Waters: Positive Momentum Rides High Again

Robust Results Lifted Waters (WAT)

Waters Corporation (WAT) Presents at U.S. All Stars Conference Transcript